EGLN2 and hematopoietic and lymphoid cell neoplasm: Loss of PHD1 catalytic activity in breast cancer cells inhibits estrogen-dependent tumorigenesis, and PHD1 depletion also impairs the fitness of lung, brain, and hematopoietic cancer lines [43].